Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.
Loading ... 
